JP2010501626A - 統合失調症を処置するためのビフェプルノックス用量 - Google Patents

統合失調症を処置するためのビフェプルノックス用量 Download PDF

Info

Publication number: JP2010501626A
Authority: JP; Japan
Prior art keywords: bifeprunox; group; treatment; patients; dose
Prior art date: 2006-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2009526089A

Other languages

English (en)

Japanese (ja)

Inventor

バルバト，ルイジ・エム

シヤピラ，ネイサン・エイ

パーデユー，ローズライン

ウインセミウス，アントジエ・エイ

ド・ブリーズ，ミシール・エイチ

デベル，マルク

ハイステルベルグ，イエンス

クログ，ジヨシアセン・メツテ

ブシユ・エステルガルド，イエツテ

マリング，ドルテ

クリステンセン，エレン・ビー

ユング，ポール・ピー

ラジエ，サンジータ

ポール，ジエフ

アーメド，サイード

ブーリン，ミシエル

キヤセイ，ダニエル・イー

ポトキン，ステイーブン・ジー

ラパポート，マーク

ニユーコマー，ジヨン

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Healthcare Products BV

Original Assignee

Abbott Healthcare Products BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-31

Filing date

2007-08-29

Publication date

2010-01-21

2007-08-29 Application filed by Abbott Healthcare Products BV filed Critical Abbott Healthcare Products BV

2010-01-21 Publication of JP2010501626A publication Critical patent/JP2010501626A/ja

Status Withdrawn legal-status Critical Current

Links

CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 title claims abstract description 464
229950009087 bifeprunox Drugs 0.000 title claims abstract description 360
201000000980 schizophrenia Diseases 0.000 title claims abstract description 101
238000011282 treatment Methods 0.000 claims abstract description 295
-1 bifeprunox compound Chemical class 0.000 claims abstract description 53
230000000694 effects Effects 0.000 claims abstract description 50
208000028017 Psychotic disease Diseases 0.000 claims abstract description 34
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 24
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
230000004584 weight gain Effects 0.000 claims abstract description 8
235000019786 weight gain Nutrition 0.000 claims abstract description 8
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims description 20
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 18
230000002411 adverse Effects 0.000 claims description 18
229910052744 lithium Inorganic materials 0.000 claims description 18
ONWKHSGOYGLGPO-UHFFFAOYSA-N methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3h-1,3-benzoxazol-2-one Chemical compound CS(O)(=O)=O.C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 ONWKHSGOYGLGPO-UHFFFAOYSA-N 0.000 claims description 18
206010012601 diabetes mellitus Diseases 0.000 claims description 13
201000001421 hyperglycemia Diseases 0.000 claims description 12
230000009798 acute exacerbation Effects 0.000 claims description 8
238000011866 long-term treatment Methods 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 5
230000002349 favourable effect Effects 0.000 claims description 5
239000004050 mood stabilizer Substances 0.000 claims description 5
229940127237 mood stabilizer Drugs 0.000 claims description 5
229960002296 paroxetine Drugs 0.000 claims description 5
208000019022 Mood disease Diseases 0.000 claims description 4
230000001430 anti-depressive effect Effects 0.000 claims description 4
239000000935 antidepressant agent Substances 0.000 claims description 4
229940005513 antidepressants Drugs 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
208000015114 central nervous system disease Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
230000002503 metabolic effect Effects 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims 1
230000001771 impaired effect Effects 0.000 claims 1
208000024891 symptom Diseases 0.000 abstract description 63
230000006872 improvement Effects 0.000 abstract description 42
230000007423 decrease Effects 0.000 abstract description 24
235000020925 non fasting Nutrition 0.000 abstract description 21
238000000034 method Methods 0.000 abstract description 19
230000005713 exacerbation Effects 0.000 abstract description 18
230000001151 other effect Effects 0.000 abstract 1
229940068196 placebo Drugs 0.000 description 348
239000000902 placebo Substances 0.000 description 348
230000008859 change Effects 0.000 description 88
229960001534 risperidone Drugs 0.000 description 58
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 58
229960005017 olanzapine Drugs 0.000 description 45
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 45
238000004458 analytical method Methods 0.000 description 34
230000003247 decreasing effect Effects 0.000 description 32
230000002159 abnormal effect Effects 0.000 description 25
230000037396 body weight Effects 0.000 description 20
206010038743 Restlessness Diseases 0.000 description 17
229940079593 drug Drugs 0.000 description 17
208000001431 Psychomotor Agitation Diseases 0.000 description 16
206010047700 Vomiting Diseases 0.000 description 16
238000011156 evaluation Methods 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
208000016261 weight loss Diseases 0.000 description 14
230000004580 weight loss Effects 0.000 description 14
208000012661 Dyskinesia Diseases 0.000 description 13
206010028813 Nausea Diseases 0.000 description 13
230000008693 nausea Effects 0.000 description 13
208000027776 Extrapyramidal disease Diseases 0.000 description 11
201000010099 disease Diseases 0.000 description 11
230000008673 vomiting Effects 0.000 description 11
102000003946 Prolactin Human genes 0.000 description 9
108010057464 Prolactin Proteins 0.000 description 9
231100000673 dose–response relationship Toxicity 0.000 description 9
229940097325 prolactin Drugs 0.000 description 9
238000012216 screening Methods 0.000 description 9
238000012423 maintenance Methods 0.000 description 8
206010010774 Constipation Diseases 0.000 description 7
239000003693 atypical antipsychotic agent Substances 0.000 description 7
229940127236 atypical antipsychotics Drugs 0.000 description 7
238000005259 measurement Methods 0.000 description 7
230000009467 reduction Effects 0.000 description 7
208000001145 Metabolic Syndrome Diseases 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
208000021017 Weight Gain Diseases 0.000 description 6
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000011260 co-administration Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
238000000306 qrs interval Methods 0.000 description 6
229940072554 risperidone 6 mg Drugs 0.000 description 6
208000031648 Body Weight Changes Diseases 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
230000004579 body weight change Effects 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
230000009429 distress Effects 0.000 description 5
208000002173 dizziness Diseases 0.000 description 5
201000006549 dyspepsia Diseases 0.000 description 5
239000008103 glucose Substances 0.000 description 5
230000007774 longterm Effects 0.000 description 5
238000004448 titration Methods 0.000 description 5
150000003626 triacylglycerols Chemical class 0.000 description 5
206010001540 Akathisia Diseases 0.000 description 4
206010019233 Headaches Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
206010037180 Psychiatric symptoms Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
208000024453 abnormal involuntary movement Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000001078 anti-cholinergic effect Effects 0.000 description 4
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
239000000812 cholinergic antagonist Substances 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000011269 treatment regimen Methods 0.000 description 4
238000002562 urinalysis Methods 0.000 description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 3
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 3
208000001089 Multiple system atrophy Diseases 0.000 description 3
150000001204 N-oxides Chemical class 0.000 description 3
206010031127 Orthostatic hypotension Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
206010042464 Suicide attempt Diseases 0.000 description 3
208000004557 Vasovagal Syncope Diseases 0.000 description 3
239000000164 antipsychotic agent Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000006870 function Effects 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
231100000869 headache Toxicity 0.000 description 3
206010022437 insomnia Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000000698 schizophrenic effect Effects 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
210000001685 thyroid gland Anatomy 0.000 description 3
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
102100036962 5'-3' exoribonuclease 1 Human genes 0.000 description 2
206010001497 Agitation Diseases 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
206010010144 Completed suicide Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 2
208000005487 Cytochrome P-450 CYP2C9 Inhibitors Diseases 0.000 description 2
208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 description 2
208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 2
102100029358 Cytochrome P450 2C9 Human genes 0.000 description 2
239000001692 EU approved anti-caking agent Substances 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
101000804879 Homo sapiens 5'-3' exoribonuclease 1 Proteins 0.000 description 2
101000654664 Homo sapiens Neuronal-specific septin-3 Proteins 0.000 description 2
101000632314 Homo sapiens Septin-6 Proteins 0.000 description 2
101000632054 Homo sapiens Septin-8 Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
102100032769 Neuronal-specific septin-3 Human genes 0.000 description 2
208000027089 Parkinsonian disease Diseases 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
206010039897 Sedation Diseases 0.000 description 2
102100027982 Septin-6 Human genes 0.000 description 2
201000001880 Sexual dysfunction Diseases 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000013019 agitation Methods 0.000 description 2
229940005529 antipsychotics Drugs 0.000 description 2
208000018300 basal ganglia disease Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
229960000623 carbamazepine Drugs 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
238000011985 exploratory data analysis Methods 0.000 description 2
229960001596 famotidine Drugs 0.000 description 2
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
229960004884 fluconazole Drugs 0.000 description 2
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
230000003400 hallucinatory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000010354 integration Effects 0.000 description 2
229960004125 ketoconazole Drugs 0.000 description 2
238000009533 lab test Methods 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000002483 medication Methods 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000011240 pooled analysis Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000036280 sedation Effects 0.000 description 2
238000010206 sensitivity analysis Methods 0.000 description 2
231100000872 sexual dysfunction Toxicity 0.000 description 2
229940045902 sodium stearyl fumarate Drugs 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
206010042772 syncope Diseases 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
CLCPWTXGFUIRJE-UHFFFAOYSA-N 7-amino-3h-1,3-benzoxazol-2-one Chemical compound NC1=CC=CC2=C1OC(=O)N2 CLCPWTXGFUIRJE-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical class C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
206010000188 Abnormal weight gain Diseases 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000219109 Citrullus Species 0.000 description 1
235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
206010054089 Depressive symptom Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010014486 Elevated triglycerides Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020400 Hostility Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000015580 Increased body weight Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000015592 Involuntary movements Diseases 0.000 description 1
206010023379 Ketoacidosis Diseases 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
206010039424 Salivary hypersecretion Diseases 0.000 description 1
208000008630 Sialorrhea Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
206010042458 Suicidal ideation Diseases 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
235000021053 average weight gain Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
238000000576 coating method Methods 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000009499 grossing Methods 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000002727 hyperosmolar Effects 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
230000008376 long-term health Effects 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
229940100466 mylicon Drugs 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
229940006350 olanzapine 15 mg Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
235000021572 root beer Nutrition 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940083037 simethicone Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229960005080 warfarin Drugs 0.000 description 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Otolaryngology (AREA)
Addiction (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2009526089A 2006-08-31 2007-08-29 統合失調症を処置するためのビフェプルノックス用量 Withdrawn JP2010501626A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US84124406P	2006-08-31	2006-08-31
EP06119936		2006-08-31
US84149506P	2006-09-01	2006-09-01
EP06120016		2006-09-01
PCT/EP2007/058958 WO2008025781A1 (en)	2006-08-31	2007-08-29	Bifeprunox doses for treating schizophrenia

Publications (1)

Publication Number	Publication Date
JP2010501626A true JP2010501626A (ja)	2010-01-21

Family

ID=38704953

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2009526089A Withdrawn JP2010501626A (ja)	2006-08-31	2007-08-29	統合失調症を処置するためのビフェプルノックス用量
JP2009526088A Withdrawn JP2010501625A (ja)	2006-08-31	2007-08-29	統合失調症を処置するためのビフェプルノックスの滴定スケジュールおよびそれにおける使用のためのキット

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009526088A Withdrawn JP2010501625A (ja)	2006-08-31	2007-08-29	統合失調症を処置するためのビフェプルノックスの滴定スケジュールおよびそれにおける使用のためのキット

Country Status (10)

Country	Link
EP (2)	EP2059245A1 (pt)
JP (2)	JP2010501626A (pt)
KR (1)	KR20090063228A (pt)
AU (2)	AU2007291234A1 (pt)
BR (1)	BRPI0715445A2 (pt)
CA (2)	CA2661120A1 (pt)
EA (1)	EA200970239A1 (pt)
IL (1)	IL196867A0 (pt)
NO (1)	NO20091243L (pt)
WO (2)	WO2008025781A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010060742A1 (en) *	2008-11-03	2010-06-03	Solvay Pharmaceuticals B.V.	Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
WO2010070061A1 (en) *	2008-12-19	2010-06-24	Abbott Healthcare Products B.V.	Compositions, kits and methods of a titration schedule for bifeprunox compounds
RS56352B2 (sr)	2009-06-25	2023-02-28	Alkermes Pharma Ireland Ltd	Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
WO2011023796A1 (en)	2009-08-31	2011-03-03	Abbott Healthcare Products B.V.	Bifeprunox for treating addiction
JP6654042B2 (ja)	2012-09-19	2020-02-26	アルカームスファーマアイルランドリミテッド	貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en)	2014-03-20	2020-01-23	Alkermes Pharma Ireland Limited	Aripiprazole formulations having increased injection speeds
CA3092335A1 (en)	2018-03-05	2019-09-12	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI9708389B8 (pt)	1996-03-29	2015-12-08	Duphar Int Res	compostos de piperazina e piperidina, composições farmacêuticas.
CA2310950C (en) *	2000-04-03	2005-11-08	Janssen Pharmaceutica N.V.	An efficacious dosage regiment of galantamine that reduces side effects
AR034206A1 (es)	2001-02-16	2004-02-04	Solvay Pharm Bv	Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
AR045362A1 (es) *	2003-08-18	2005-10-26	Solvay Pharm Bv	Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona
US7423040B2 (en) *	2005-02-18	2008-09-09	Irene Eijgendaal	Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
PT1919883E (pt)	2005-08-22	2009-03-26	Solvay Pharm Bv	N-óxidos como pró-medicamentos de derivados de piperazina & piperidina

2007
- 2007-08-29 CA CA002661120A patent/CA2661120A1/en not_active Abandoned
- 2007-08-29 AU AU2007291234A patent/AU2007291234A1/en not_active Abandoned
- 2007-08-29 EP EP07802975A patent/EP2059245A1/en not_active Withdrawn
- 2007-08-29 WO PCT/EP2007/058958 patent/WO2008025781A1/en active Application Filing
- 2007-08-29 CA CA002661800A patent/CA2661800A1/en not_active Abandoned
- 2007-08-29 JP JP2009526089A patent/JP2010501626A/ja not_active Withdrawn
- 2007-08-29 KR KR1020097006567A patent/KR20090063228A/ko not_active Application Discontinuation
- 2007-08-29 AU AU2007291235A patent/AU2007291235A1/en not_active Abandoned
- 2007-08-29 EA EA200970239A patent/EA200970239A1/ru unknown
- 2007-08-29 EP EP07802974A patent/EP2059244A1/en not_active Withdrawn
- 2007-08-29 WO PCT/EP2007/058957 patent/WO2008025780A1/en active Application Filing
- 2007-08-29 BR BRPI0715445-3A patent/BRPI0715445A2/pt not_active IP Right Cessation
- 2007-08-29 JP JP2009526088A patent/JP2010501625A/ja not_active Withdrawn
2009
- 2009-02-03 IL IL196867A patent/IL196867A0/en unknown
- 2009-03-25 NO NO20091243A patent/NO20091243L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2661120A1 (en)	2008-03-06
NO20091243L (no)	2009-03-25
EA200970239A1 (ru)	2009-08-28
JP2010501625A (ja)	2010-01-21
KR20090063228A (ko)	2009-06-17
BRPI0715445A2 (pt)	2014-05-13
WO2008025780A1 (en)	2008-03-06
AU2007291235A1 (en)	2008-03-06
WO2008025781A1 (en)	2008-03-06
EP2059244A1 (en)	2009-05-20
CA2661800A1 (en)	2008-03-06
IL196867A0 (en)	2009-11-18
AU2007291234A1 (en)	2008-03-06
EP2059245A1 (en)	2009-05-20

Publication	Publication Date	Title
TWI776407B (zh)	2022-09-01	激動劑形成之調配物及使用其之方法
US7749993B2 (en)	2010-07-06	Method for treating severe heart failure and medicament therefor
US20110070319A1 (en)	2011-03-24	Bifeprunox doses for treating schizophrenia
JP2010501626A (ja)	2010-01-21	統合失調症を処置するためのビフェプルノックス用量
US20180311217A1 (en)	2018-11-01	Methods of treatment and compositions with xanthine oxidase inhibitors
WO2013096870A1 (en)	2013-06-27	Compositions and methods for treating amyotrophic lateral sclerosis
US20120289560A1 (en)	2012-11-15	Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
JP6499634B2 (ja)	2019-04-10	過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
US20120289564A1 (en)	2012-11-15	Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
US20050203124A1 (en)	2005-09-15	Compounds for the sustained reduction of body weight
AU2016301689B2 (en)	2018-10-04	Ameliorating agent for detrusor hyperactivity with impaired contractility
US20120289547A1 (en)	2012-11-15	Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
CN101573117A (zh)	2009-11-04	用于治疗精神分裂症的联苯芦诺剂量
MX2013013124A (es)	2014-02-27	Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
US20120289561A1 (en)	2012-11-15	Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder
US20120289563A1 (en)	2012-11-15	Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder

Legal Events

Date	Code	Title	Description
2010-08-21	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100820
2011-04-20	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110419
2011-05-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110418

Date

Code

Title

Description

2010-08-21

A621

Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100820

2011-04-20

A761

Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110419

2011-05-10

A521

Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110418